Giovanni Marchegiani: Perioperative modified FOLFIRINOX for pancreas cancer

Giovanni Marchegiani, Pancreas Surgeon at The University of Padua, made the following post on X:

“Perioperative modified FOLFIRINOX for resectable pancreas cancer

•  Non randomized trial 46 pts
• 72% underwent surgery
• 12 months PFS 67%
• Postoperative ctDNA positivity was strongly associated with recurrence.”

Syed A. Ahmad, Director at University of Cincinnati Cancer Center & Chief of Surgical Oncology at University of Cincinnati, retweeted the post, adding the following:

“Interesting results. Similar to our SWOG Cancer Research Network 1505 trial with % completing upfront tx, low % of adj, and getting surgery but sig longer mOS (37.2 v. 22.4 mo). Wonder if pts getting surgery off protocol and included in ITT affected results? Will need to read paper.”

Read further.
Source: Giovanni Marchegiani/X and Syed A. Ahmad/X
.